Literature DB >> 7969121

Transactivation of the human p53 tumor suppressor gene by c-Myc/Max contributes to elevated mutant p53 expression in some tumors.

B Roy1, J Beamon, E Balint, D Reisman.   

Abstract

Elevated levels of mutant forms of the p53 tumor suppressor are a hallmark of many transformed cells. Multiple mechanisms such as increased stability of the protein and increased transcription of the gene can account for elevated p53 expression. Recent findings indicate that c-Myc/Max heterodimers can bind to an essential CA(C/T)GTG-containing site in the p53 promoter and elevate its expression. We have addressed the possibility that elevated mutant p53 expression is due to deregulated c-Myc expression. Here we demonstrate that the human p53 promoter is transactivated by high c-Myc expression and repressed by high Max expression. In examining the relative levels of c-Myc and p53 in human Burkitt's lymphomas and other B-lymphoid lines, we found that there is a correlation between the levels of c-Myc protein and p53 mRNA expression. In particular, cells that express very low levels of c-Myc protein also express low levels of p53 mRNA, while cells that express high levels of c-Myc tend to express high levels of p53 mRNA. To determine whether the p53 gene can be a target for c-Myc in vivo, we assayed the effects of antisense c-myc RNA on the levels of endogenous p53 mRNA. The results indicate that the presence of antisense c-myc RNA leads to a reduction in the levels of c-Myc protein, p53 mRNA, and expression from the p53 promoter. Taken together, our findings support a direct role for c-Myc in elevating expression of the mutant p53 gene in some tumors.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7969121      PMCID: PMC359320          DOI: 10.1128/mcb.14.12.7805-7815.1994

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  92 in total

1.  An amino-terminal c-myc domain required for neoplastic transformation activates transcription.

Authors:  G J Kato; J Barrett; M Villa-Garcia; C V Dang
Journal:  Mol Cell Biol       Date:  1990-11       Impact factor: 4.272

2.  Cell cycle control of p53 in normal (3T3) and chemically transformed (Meth A) mouse cells. II. Requirement for cell cycle progression.

Authors:  W Deppert; G Buschhausen-Denker; T Patschinsky; K Steinmeyer
Journal:  Oncogene       Date:  1990-11       Impact factor: 9.867

3.  Subcellular distribution of the p53 protein during the cell cycle of Balb/c 3T3 cells.

Authors:  G Shaulsky; A Ben-Ze'ev; V Rotter
Journal:  Oncogene       Date:  1990-11       Impact factor: 9.867

4.  Genetic mechanisms of tumor suppression by the human p53 gene.

Authors:  P L Chen; Y M Chen; R Bookstein; W H Lee
Journal:  Science       Date:  1990-12-14       Impact factor: 47.728

5.  Gene expression in melanoma cell lines and cultured melanocytes: correlation between levels of c-src-1, c-myc and p53.

Authors:  G Chenevix-Trench; N G Martin; K A Ellem
Journal:  Oncogene       Date:  1990-08       Impact factor: 9.867

6.  Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene.

Authors:  L Raycroft; H Y Wu; G Lozano
Journal:  Science       Date:  1990-08-31       Impact factor: 47.728

7.  Sequence-specific DNA binding by the c-Myc protein.

Authors:  T K Blackwell; L Kretzner; E M Blackwood; R N Eisenman; H Weintraub
Journal:  Science       Date:  1990-11-23       Impact factor: 47.728

8.  Presence of a potent transcription activating sequence in the p53 protein.

Authors:  S Fields; S K Jang
Journal:  Science       Date:  1990-08-31       Impact factor: 47.728

9.  Methylation-sensitive sequence-specific DNA binding by the c-Myc basic region.

Authors:  G C Prendergast; E B Ziff
Journal:  Science       Date:  1991-01-11       Impact factor: 47.728

10.  Negative autoregulation of c-myc gene expression is inactivated in transformed cells.

Authors:  F Grignani; L Lombardi; G Inghirami; L Sternas; K Cechova; R Dalla-Favera
Journal:  EMBO J       Date:  1990-12       Impact factor: 11.598

View more
  25 in total

1.  Differential binding of NF1 transcription factor to P53 gene promoter and its depletion in human breast tumours.

Authors:  B K Nayak; B R Das
Journal:  Mol Biol Rep       Date:  1999-12       Impact factor: 2.316

2.  c-Myc is necessary for DNA damage-induced apoptosis in the G(2) phase of the cell cycle.

Authors:  S Adachi; A J Obaya; Z Han; N Ramos-Desimone; J H Wyche; J M Sedivy
Journal:  Mol Cell Biol       Date:  2001-08       Impact factor: 4.272

3.  Quantitative analysis of chromosomal CGH in human breast tumors associates copy number abnormalities with p53 status and patient survival.

Authors:  A N Jain; K Chin; A L Børresen-Dale; B K Erikstein; P Eynstein Lonning; R Kaaresen; J W Gray
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-03       Impact factor: 11.205

4.  YY1 and NF1 both activate the human p53 promoter by alternatively binding to a composite element, and YY1 and E1A cooperate to amplify p53 promoter activity.

Authors:  E E Furlong; T Rein; F Martin
Journal:  Mol Cell Biol       Date:  1996-10       Impact factor: 4.272

Review 5.  c-Myc target genes involved in cell growth, apoptosis, and metabolism.

Authors:  C V Dang
Journal:  Mol Cell Biol       Date:  1999-01       Impact factor: 4.272

6.  Identification and characterization of the human NOL7 gene promoter.

Authors:  Tanmayi P Mankame; Guolin Zhou; Mark W Lingen
Journal:  Gene       Date:  2010-03-03       Impact factor: 3.688

7.  Myc versus USF: discrimination at the cad gene is determined by core promoter elements.

Authors:  K E Boyd; P J Farnham
Journal:  Mol Cell Biol       Date:  1997-05       Impact factor: 4.272

8.  Myc represses transcription of the growth arrest gene gas1.

Authors:  T C Lee; L Li; L Philipson; E B Ziff
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-25       Impact factor: 11.205

9.  The human T-cell leukemia virus type-1 p30II protein activates p53 and induces the TIGAR and suppresses oncogene-induced oxidative stress during viral carcinogenesis.

Authors:  Megan Romeo; Tetiana Hutchison; Aditi Malu; Averi White; Janice Kim; Rachel Gardner; Katie Smith; Katherine Nelson; Rachel Bergeson; Ryan McKee; Carolyn Harrod; Lee Ratner; Bernhard Lüscher; Ernest Martinez; Robert Harrod
Journal:  Virology       Date:  2018-02-20       Impact factor: 3.616

10.  Switch from Mnt-Max to Myc-Max induces p53 and cyclin D1 expression and apoptosis during cholestasis in mouse and human hepatocytes.

Authors:  Heping Yang; Tony W H Li; Kwang Suk Ko; Meng Xia; Shelly C Lu
Journal:  Hepatology       Date:  2009-03       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.